ALCHEMIA RAISES $15 MILLION FOR SPINOFF

Written on the 7 November 2011

ALCHEMIA RAISES $15 MILLION FOR SPINOFF

BIOTECHNOLOGY company Alchemia plans to use proceeds from a global institutional placement towards its proposed de-merger from subsidiary Alchemia Oncology.

Alchemia CEO Pete Smith (pictured) says the de-merged Alchemia Oncology, formerly known as Meditec, will become a separate entity listed on Australian, US or both stock exchanges.

“The stand-alone company will contain all of the HyACT oncology assets including HAIrinotecan,” says Smith.

“We are keeping an open eye on M&A opportunities and will take advice on potentially listing on the (US stock exchange) NASDAQ.”

The $15 million placement involved issuing 62.5 million shares for $0.24 per unit, representing a 20 per cent discount to the 20-day volume-weighted average price of Alchemia shares traded on ASX to November 3.

Smith says the institutional placement was oversubscribed.

“(There was) strong demand from international, existing and new investors – and included a number of leading specialist life sciences funds joining the Alchemia register,” he says.

Alchemia will offer investors a chance to subscribe for up to $15,000 in stocks under a new share purchase plan (SPP), with a 7.5 per cent discount on the five-day average closing price on the ASX.

The placement also gives the company’s largest shareholder group, Orbis Investment Management an opportunity to maintain its stake.

“This may involve the issue of additional shares to Orbis to enable Orbis to maintain its shareholding at 19.1 per cent, following completion of the SPP and settlement of the second tranche of the placement,” says Smith.

Proceeds from the capital raising will be used towards clinical development, research and working capital purposes including the spin out and listing of Alchemia Oncology, business development of HA-Irinotecan and costs relating to the raising.

RBS Morgans acted as lead manager, Corrs Chambers Westgarth partners Stephanie Daveson and Jeremy Horwood served as the legal counsels and Blueprint Life Science Group was the corporate adviser.

Alchemia will continue to be listed on the ASX after the demerger, with fondaparinux being the primary asset of the company.

“By separating the oncology business from Alchemia, we aim to allow the majority of profits arising from fondaparinux to fall to Alchemia’s bottom line,” says Smith.

“We anticipate initiating patient recruitment to our Phase III trial and commencement of preparations to demerge as soon as possible after the fundraising.”

The company may opt to rationalise its cost structure, while managing ongoing relationship with manufacturing and marketing partner Dr Reddy’s Laboratories.

Alchemia reported fiscal 2011 tax losses of $72 million, while Alchemia Oncology suffered losses of $52 million with the burden to be carried by the subsidiary after the spin-out is complete.

The deal is expected to close by the end of 2011.


Latest News

BRAMBLES TUMBLES AFTER REDUCING GUIDANCE

BRAMBLES (ASX: BXB) will miss its first-half guidance due to cost pressures at its North America business.

The com...

VILLAGE ROADSHOW PARKS HURT BY DREAMWORLD TRAGEDY

QUEENSLAND visitors to Village Roadshow (ASX: VRL) theme parks have declined 12 per cent in the wake of four deaths a...

ASF UNVEILS TRAFFIC PLANS FOR THE SPIT

A SECOND bridge over the Nerang River is the centrepiece of the ASF Consortium's plan to improve traffic flow ...

BHP AND VALE EDGE CLOSER TO $47.5 BILLION SAMARCO DAM DISASTER SETTLEMENT

BHP Billiton (ASX: BHP) and Brazilian mining company Vale have entered into a preliminary agreement with Brazilian fe...

Related News

CARSALES CEO RETIRES AS NEW COMPETITOR COX FINALISES MERGER

CARSALES will have a new CEO as it takes on a fresh challenger to its crown as the dominant online car sales portal i...

BUSINESS CONFIDENCE AT A SIX-YEAR HIGH

SMALL and medium businesses have entered 2017 with their confidence at a six-year high, building on strong gains m...

CONSUMERS PESSIMISTIC ENTERING 2017

CONSUMER confidence remains at its weakest point since April 2016, according to the latest Westpac Melbourne Institut...

RISE OF STARTUP SUPPORT PROGRAMS NOT AS ROSY AT IT SEEMS

ENTREPRENEURIAL cultivation companies in Australia are appearing quickly, but questions have been raised about whe...

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter